

## WHAT IS CLAIMED IS:

1. A method for treatment of a patient, the method comprising:  
providing a vascular prosthesis comprising a structure and at least one source of at least one therapeutic capable agent associated with the structure;  
implanting the vascular prosthesis within the patient's vasculature including a susceptible tissue site;  
releasing the at least one therapeutic capable agent.
2. The method of Claim 1, wherein releasing comprises releasing at least one therapeutic capable agent selected from the group consisting of immunosuppressants, anti-inflammatories, anti-proliferatives, anti-migratory agents, anti-fibrotic agents, proapoptotics, vasodilators, calcium channel blockers, anti-neoplastics, anti-cancer agents, antibodies, anti-thrombotic agents, anti-platelet agents, IIb/IIIa agents, antiviral agents, MTOR (mammalian target of rapamycin) inhibitors, non-immunosuppressant agents, tyrosine kinase inhibitors, CDK inhibitors, bisphosphonates, NF- $\kappa$ B Decoy Oligo, proteins, oligomers, amino acids, peptides, genes, growth factors, anti-sense, and combinations thereof.
3. The method of Claim 1, wherein releasing comprises releasing at least one therapeutic capable agent selected from the group consisting of mycophenolic acid; mycophenolic acid derivatives including 2-methoxymethyl derivative, 2-methyl derivative, and sodium mycophenolic acid; VX-148; VX-944; mycophenolate mofetil; mizoribine; methylprednisolone; dexamethasone; rapamycin; rapamycin analogs or derivatives including AP23573, RAPALOGS™ including AP21967, deuterated rapamycin, ABT-578, CERTICAN™, 32-deoxorapamycin, CCI - 779; ABT-773, ABT-797, TRIPTOLIDE™; METHOTREXATE™; phenylalkylamines including verapamil; benzothiazepines including diltiazem; 1,4-dihydropyridines including benidipine, nifedipine, nicardipine, isradipine, felodipine, amlodipine, nilvadipine, nisoldipine, manidipine, nitrendipine, barnidipine; ASCOMYCIN™; PIMECROLIMUS™; WORTMANNIN™; LY294002; CAMPTOTHECIN™; silibinin; silymarin; baicalein; histone deacetylase including trichostatin A; PD-0183812; butyrolactone I substituted purines including olomoucine, CGP74514, and its derivatives; polyhydroxylated flavones including flavopyridol; oxindole inhibitors including GW-8510, GW-2059, GW-5181; indolinone derivatives including SU-

5416; Zoledronic acids including ZOMETA™, Zoledronate, and (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate; isoquinoline; HA-1077 (1-(5-isoquinolinesulfonyl)-homopiperazine hydrochloride); TAS-301; TOPOTECAN™; hydroxyurea; TACROLIMUS™; cyclophosphamide; cyclosporine; daclizumab; azathioprine; prednisone; diferuloylmethane; diferuloylmethane; diferulymethane; GEMCITABINE™; cilostazol; TRANILAST™; enalapril; quercetin; suramin; estradiol; cycloheximide; tiazofurin; zafurin; benidipine hydrochloride; phenylaminopyrimidine derivatives including Imatinib mesylate; other tyrosine inhibitors such as 4-[6-methoxy-7-(3-piperidine-1-yl-propoxy)-quinazolin-4-yl]-piperazine-1-carboxylic acid (4-isopropoxyphenyl) amide (CT53518 or MLN518 from Millennium Pharmaceutical), 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone (SU6656), 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone (SU5614 from Sugen), a water-soluble N,N-dimethylglycine ester prodrug CEP7055 that converts to CEP5214 in vivo from Cephalon, West Chester PA, 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2 or AG1879), 6,7-Dimethyl-2-phenylquinoxaline (AG1295), Tautomycin™, Radicicol, Damnacanthal, Herbimycin A, 6-(2,6-dichloro-phenyl)-8-methyl-2-(3-methylsulfonyl-phenylamino)-8h-pyrido(2,3-d)pyrimidin-7-one (PD173955 from Parke-Davis), PD166326, PD183805, 4-[(3-Bromophenyl)amino]-6-propionylamidoquinazoline (PD174265), 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone (PD153035), 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline (PD168393), TARCEVA™ (erlotinib HCl), CI-1033, AEE788, CP-724,714 (from OSI Pharmaceutical), Geldanamycin, 17-(allylamino)-17-demethoxygeldanamycin (17-AG or 12-AAG), Tarceva™, Iressa™, and ZD4910; EGFR/ErbB2 inhibitor (CI1033; EKB569; GW2016; PKI166); VEGF receptor inhibitors (ZK222584; ZD6474); VEGFR/FGFR/PDGFR inhibitors (SU6668; SU11248; PTK787), NGF receptor inhibitors (CEP2583); anti-EGF receptor MAbs (MAb225/Erbitux™); anti-ErbB2 MAbs (MAb4D5/Herceptin™); Avastin™, an anti-VEGF MAb; bisphosphonates; NF-κB Decoy oligonucleotides; proteins including albumin; genes including TSC1, TSC2, hamartin, and KIAA0243; growth factors including VEGF, EGF, PDGF, and FGF; anti-sense including antisense phosphorothioate oligodeoxynucleotide; anti-bodies including anti-MTOR, anti-p27, anti-p53, and anti-Cdk; metabolites and derivatives thereof; and therapeutic capable agents incorporated in a vector including HIV Envelope vector; and combinations thereof.

4. The method of Claim 1, wherein the at least one therapeutic capable agent includes an active compound, a pro-drug of the active compound, a metabolite of the active compound, a derivative of the active compound, an analogue of the active compound, or a combination thereof.

5. The method of Claim 1, wherein the at least one therapeutic capable agent is released within a time period from about the first day to about 200<sup>th</sup> day from the implanting of the prosthesis.

6. The method of Claim 1, wherein the at least one therapeutic capable agent is released at a total amount ranging from about 0.1 µg to about 10 g.

7. The method of Claim 1, wherein the at least one therapeutic capable agent is released at a rate between about 0.001 µg/day to about 500 µg/day.

8. The method of Claim 1, wherein the structure has a luminal facing surface and a tissue facing surface.

9. The method of Claim 8, wherein the at least one therapeutic capable agent is associated with the structure only at one of the luminal and tissue facing surfaces.

10. The method of Claim 8, wherein the at least one therapeutic capable agent is associated with the structure at the tissue facing surface.

11. The method of Claim 8, wherein the at least one therapeutic capable agent is associated with the structure at both luminal and tissue facing surfaces.

12. The method of Claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate a mammalian tissue concentration ranging from about 0.15 ng of therapeutic capable agent / mg of tissue to about 3 ng of therapeutic capable agent / mg of tissue.

13. The method of Claim 4 or 12, wherein the therapeutic capable agent comprises mycophenolic acid.

14. The method of Claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate an unwanted

metabolite of the therapeutic capable agent having a mammalian tissue concentration of less than 2.5 ng/ mg of tissue.

15. The method of Claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 1.1 ng/ mg of tissue.

16. The method of Claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 0.5 ng/ mg of tissue.

17. The method of Claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 0.25 ng/ mg of tissue.

18. The method of Claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 0.10 ng/ mg of tissue.

19. The method of Claim 1, wherein releasing comprises releasing the at least one therapeutic capable agent to the susceptible tissue site to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of substantially zero.

20. A device for intracorporeal use, the device comprising:  
an expandable structure; and  
at least one source of at least one therapeutic capable agent associated with the structure.

21. The device of Claim 20, wherein the expandable structure has a luminal facing surface and a tissue facing surface.

22. The device of Claim 21, wherein the at least one therapeutic capable agent is associated with the expandable structure only on one of the luminal and tissue facing surfaces.

23. The device of Claim 21, wherein the at least one therapeutic capable agent is associated with the expandable structure on the tissue facing surface.

24. The device of Claim 21, wherein the at least one therapeutic capable agent is associated with the expandable structure on both luminal and tissue facing surfaces.

25. The device of Claim 21, wherein the at least one source is disposed adjacent at least one of the luminal or tissue facing surfaces of the expandable structure.

26. The device of Claim 21, wherein the at least one source is a reservoir disposed adjacent the expandable structure.

27. The device of Claim 26, wherein the reservoir is at least partially on either or both the luminal and the tissue facing surfaces of the expandable structure.

28. The device of Claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent at a phase to a susceptible tissue site of a mammalian intracorporeal body to effectuate a mammalian tissue concentration ranging from about 0.001 ng of therapeutic capable agent / mg of tissue to about 100 µg of therapeutic capable agent / mg of tissue.

29. The device of Claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate a mammalian tissue concentration ranging from about 0.15 ng of therapeutic capable agent / mg of tissue to about 3 ng of therapeutic capable agent / mg of tissue.

30. The device of Claim 20 or 29, wherein the therapeutic capable agent is mycophenolic acid.

31. The device of Claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian

intracorporeal body to effectuate an unwanted metabolite of the therapeutic capable agent having a mammalian tissue concentration of less than 2.5 ng/ mg of tissue.

32. The device of Claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 1.1 ng/ mg of tissue.

33. The device of Claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 0.5 ng/ mg of tissue.

34. The device of Claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 0.25 ng/ mg of tissue.

35. The device of Claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of less than 0.10 ng/ mg of tissue.

36. The device of Claim 20, wherein the device is configured to deliver the at least one therapeutic capable agent to a susceptible tissue site of a mammalian intracorporeal body to effectuate an unwanted metabolite of the therapeutic capable agent having a concentration in the mammalian tissue of substantially zero.

37. The device of Claim 20, wherein the at least one therapeutic capable agent is selected from the group consisting of immunosuppressants, anti-inflammatories, anti-proliferatives, anti-migratory agents, anti-fibrotic agents, proapoptotics, vasodilators, calcium channel blockers, anti-neoplastics, anti-cancer agents, antibodies, anti-thrombotic agents, anti-platelet agents, IIb/IIIa agents, antiviral agents, MTOR (mammalian target of rapamycin) inhibitors, non-immunosuppressant agents, tyrosine kinase inhibitors, EGFR/ErbB2 inhibitors, VEGF receptor inhibitors, VEGFR/FGFR/PDGFR inhibitors, NGF receptor inhibitors, anti-EGF receptor MAb, anti-ErbB2 MAb, CDK inhibitors, bisphosphonates,

NF- $\kappa$ B Decoy Oligo, proteins, oligomers, amino acids, peptides, genes, growth factors, anti-sense, and a combination thereof.

38. The device of Claim 20, wherein releasing comprises releasing at least one therapeutic capable agent selected from the group consisting of mycophenolic acid; mycophenolic acid derivatives including 2-methoxymethyl derivative, 2-methyl derivative, and sodium mycophenolic acid; VX-148; VX-944; mycophenolate mofetil; mizoribine; methylprednisolone; dexamethasone; rapamycin; deuterated rapamycin; rapamycin analogs or derivatives including AP23573, RAPALOGS™ including AP21967, CERTICAN™, 32-deoxorapamycin, ABT-578, CCI - 779; ABT-773; ABT-797; TRIPTOLIDE™; METHOTREXATE™; phenylalkylamines including verapamil; benzothiazepines including diltiazem; 1,4-dihydropyridines including benidipine, nifedipine, nicardipine, isradipine, felodipine, amlodipine, nilvadipine, nisoldipine, manidipine, nitrendipine, barnidipine; ASCOMYCIN™; PIMECROLIMUS™; WORTMANNIN™; LY294002; CAMPTOTHECIN™; silibinin; sylymarin; baicalein; histone deacetylase including trichostatin A; PD-0183812; butyrolactone I substituted purines including olomoucine, *CGP74514*, and its derivatives; polyhydroxylated flavones including flavopyridol; oxindole inhibitors including *GW-8510*, *GW-2059*, *GW-5181*; indolinone derivatives including *SU-5416*; Zoledronic acids including ZOMETA™, Zoledronate, and (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate; isoquinoline; HA-1077 (1-(5-isoquinolinesulfonyl)-homopiperazine hydrochloride); TAS-301; TOPOTECAN™; hydroxyurea; TACROLIMUS™; cyclophosphamide; cyclosporine; daclizumab; azathioprine; prednisone; diferuloymethane; diferuloymethane; diferulylmethane; GEMCITABINE™; cilostazol; TRANILAST™; enalapril; quercetin; suramin; estradiol; cycloheximide; tiazofurin; zafurin; benidipine hydrochloride; phenylaminopyrimidine derivatives including Imatinib mesylate; other tyrosine inhibitors such as 4-[6-methoxy-7-(3-piperidine-1-yl-propoxy)-quinazolin-4-yl]-piperazine-1-carboxylic acid(4-isopropoxyphenyl) amide (CT53518 or MLN518 from Millennium Pharmaceutical), 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone (SU6656), 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone (SU5614 from Sugen), a water-soluble N,N-dimethylglycine ester prodrug CEP7055 that converts to CEP5214 in vivo from Cephalon, West Chester PA, 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2 or AG1879), 6,7-Dimethyl-2-phenylquinoxaline (AG1295), Tautomycin™, Radicicol, Damnacanthal, Herbimycin A, 6-

(2,6-dichloro-phenyl)-8-methyl-2-(3-methylsulfanyl- phenylamino)-8h-pyrido(2,3-d)pyrimidin-7-one (PD173955 from Parke-Davis), PD166326, PD183805, 4-[(3-Bromophenyl)amino]-6-propionylamidoquinazoline (PD174265), 5-Chloro-3-[(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone (PD153035), 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline (PD168393), TARCEVA™ (erlotinib HCl), CI-1033, AEE788, CP-724,714 (from OSI Pharmaceutical), Geldanamycin, 17-(allylamino)-17-demethoxygeldanamycin (17-AG or 12-AAG), Tarceva™, Iressa™, and ZD4910, EGFR/ErbB2 inhibitor (CI1033; EKB569; GW2016; PKI166), VEGF receptor inhibitors (ZK222584;ZD6474), VEGFR/FGFR/PDGFR inhibitors (SU6668; SU11248; PTK787), NGF receptor inhibitors (CEP2583), anti-EGF receptor MAbs (MAb225/Erbitux™), anti-ErbB2 MAbs (MAb4D5/Herceptin™), Avastin™, an anti-VEGF MAb, bisphosphonates; NF-κB Decoy oligonucleotides; proteins including albumin; genes including TSC1, TSC2, hamartin, and KIAA0243; growth factors including VEGF, EGF, PDGF, and FGF; anti-sense including antisense phosphorothioate oligodeoxynucleotide; anti-bodies including anti-MTOR, anti-p27, anti-p53, and anti-Cdk; metabolites and derivatives thereof; and therapeutic capable agents incorporated in a vector including HVJ Envelop vector; and combinations thereof.